EPS for resTORbio, Inc. (TORC) Expected At $-0.42

July 14, 2018 - By Mary Markley

Analysts expect resTORbio, Inc. (NASDAQ:TORC) to report $-0.42 EPS on August, 9.After having $-0.46 EPS previously, resTORbio, Inc.’s analysts see -8.70 % EPS growth. The stock increased 0.22% or $0.02 during the last trading session, reaching $9.15. About 107,156 shares traded. resTORbio, Inc. (NASDAQ:TORC) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company has market cap of $256.62 million. The Company’s lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. It currently has negative earnings. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system.

More notable recent resTORbio, Inc. (NASDAQ:TORC) news were published by: Seekingalpha.com which released: “resTORbio – Leading The Charge Against Aging Related Diseases” on July 13, 2018, also Nasdaq.com with their article: “resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune …” published on July 11, 2018, Investingnews.com published: “Biotech Update: Q2 2018 in Review” on July 11, 2018. More interesting news about resTORbio, Inc. (NASDAQ:TORC) were released by: Benzinga.com and their article: “44 Biggest Movers From Yesterday” published on July 12, 2018 as well as Bizjournals.com‘s news article titled: “Goodwin dominates this year’s record batch of Mass. biotech IPOs” with publication date: July 03, 2018.

resTORbio, Inc. (NASDAQ:TORC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.